LN
Clinical trials for LN explained in plain language.
Never miss a new study
Get alerted when new LN trials appear
Sign up with your email to follow new studies for LN, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Promising kidney drug trial halted early – what it means for patients
Disease control TerminatedThis study tested a drug called ALXN2050 in 100 adults with kidney inflammation caused by lupus or IgA nephropathy. The goal was to see if it could reduce protein in the urine, a sign of kidney damage. Participants took the drug or a placebo for up to 50 weeks. The trial was stop…
Matched conditions: LN
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 12, 2026 13:42 UTC
-
Experimental drug targets protein leak in kidney patients
Disease control TerminatedThis study tested a drug called OMS721 (narsoplimab) in 31 people with four types of kidney disease: IgA nephropathy, lupus nephritis, membranous nephropathy, and C3 glomerulopathy. The main goal was to see if the drug is safe and if it reduces protein in the urine, a sign of kid…
Matched conditions: LN
Phase: PHASE2 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated May 11, 2026 20:49 UTC